Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00847990 · ClinicalTrials.gov registry record
Non-Invasive Screening for Fetal Aneuploidy
A clinical trial, sponsored by Sequenom.
- Completed
- Registry status
- 5,000
- Enrollment target
NCT00847990 is a clinical trial that has completed, run by Sequenom. The registered enrollment target is 5,000 participants.
The verdict
NCT00847990 has completed, sponsored by Sequenom.
- COMPLETED
- Registry status
- 5,000 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if a laboratory test developed by the Sequenom Center for Molecular Medicine (SCMM) that uses a new marker found in the mother's blood can better identify pregnancies that have a child with a chromosome abnormality such as Down syndrome (Trisomy 21), Edwards syndrome (Trisomy 18), or other chromosome abnormality.
Interventions
- OTHER Maternal blood screening test for fetal aneuploidy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5,000 participants |
| Start Date | 2009-03 |
| Est. Completion | 2011-08 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00847990
The ClinicalTrials.gov registry entry for NCT00847990 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 5,000 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sequenom, which has 26 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Maternal blood screening test for fetal aneuploidy is the first listed.
NCT00847990 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00847990 about?
NCT00847990 is a clinical study titled "Non-Invasive Screening for Fetal Aneuploidy". The purpose of this study is to determine if a laboratory test developed by the Sequenom Center for Molecular Medicine (SCMM) that uses a new marker found in the mother's blood can better identify pregnancies that have a child with a chromosome abnormality such as Down syndrome (Trisomy 21), Edwards...
What is the current status of trial NCT00847990?
This trial is currently completed. The enrollment target is 5,000 participants. The study started on 2009-03. Estimated completion is 2011-08.
What interventions are being tested in trial NCT00847990?
The interventions under investigation include: Maternal blood screening test for fetal aneuploidy (OTHER).
Who is sponsoring clinical trial NCT00847990?
This trial is sponsored by Sequenom, which has 26 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.